CD248抗体—艾普蒂 新品

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using CD248 mouse mAb (green) and negative control (red).    

  
  

CD248. also known as endosialin or tumor endothelial marker 1 (TEM1), is a transmembrane glycoprotein belonging to the C-type lectin family. It is primarily expressed on stromal cells, including fibroblasts, pericytes, and mesenchymal stem cells, as well as certain tumor cells. CD248 plays roles in cell adhesion, migration, and proliferation, and is implicated in tumor angiogenesis, extracellular matrix remodeling, and tissue repair. Its overexpression has been linked to tumor progression, metastasis, and poor prognosis in cancers like sarcoma, breast cancer, and glioblastoma. In non-cancerous contexts, CD248 is associated with fibrotic diseases, inflammation, and wound healing.

CD248 antibodies are tools developed to target this protein for research or therapeutic purposes. Monoclonal and polyclonal antibodies against CD248 are used in immunohistochemistry, flow cytometry, and Western blotting to study its expression patterns and biological functions. Therapeutically, CD248 antibodies aim to block its activity in pathological conditions. Preclinical studies suggest that anti-CD248 agents may inhibit tumor growth by disrupting stromal-tumor interactions or inducing antibody-dependent cellular cytotoxicity (ADCC). Additionally, they are explored for treating fibrosis by targeting profibrotic stromal cells.

Research on CD248 antibodies has expanded due to their potential as biomarkers for disease monitoring and targeted therapy. However, challenges remain in understanding its precise mechanisms and ensuring specificity in complex microenvironments. Ongoing studies focus on optimizing antibody design and evaluating efficacy in clinical trials.